Barclays PLC Purchases 11,316 Shares of Neurogene Inc. (NASDAQ:NGNE)

Barclays PLC boosted its position in Neurogene Inc. (NASDAQ:NGNE) by 319.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,859 shares of the company’s stock after buying an additional 11,316 shares during the quarter. Barclays PLC owned approximately 0.10% of Neurogene worth $623,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after purchasing an additional 659,515 shares during the last quarter. Jennison Associates LLC bought a new position in Neurogene in the third quarter valued at $3,300,000. Integral Health Asset Management LLC bought a new stake in Neurogene during the 2nd quarter worth about $2,547,000. RTW Investments LP boosted its stake in shares of Neurogene by 6.0% during the 3rd quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock worth $47,635,000 after buying an additional 64,691 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its holdings in shares of Neurogene by 123.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after acquiring an additional 56,533 shares in the last quarter. Institutional investors own 52.37% of the company’s stock.

Insider Transactions at Neurogene

In other news, major shareholder Samsara Biocapital Gp, Llc bought 48,770 shares of the stock in a transaction dated Tuesday, November 26th. The shares were bought at an average price of $25.83 per share, for a total transaction of $1,259,729.10. Following the completion of the purchase, the insider now owns 1,717,127 shares in the company, valued at approximately $44,353,390.41. This trade represents a 2.92 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rachel Mcminn purchased 47,500 shares of Neurogene stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $20.40 per share, with a total value of $969,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,297,859 shares in the company, valued at $26,476,323.60. This trade represents a 3.80 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 120,270 shares of company stock worth $2,720,249. 9.92% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NGNE. Robert W. Baird increased their price target on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Leerink Partners increased their price objective on Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Stifel Nicolaus raised their target price on shares of Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Neurogene in a research report on Monday, November 25th. Finally, BMO Capital Markets decreased their price objective on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $60.83.

Neurogene Stock Down 4.9 %

NGNE stock opened at $17.63 on Friday. Neurogene Inc. has a one year low of $14.44 and a one year high of $74.49. The company has a fifty day moving average price of $26.30 and a two-hundred day moving average price of $36.48.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.